- $1.29bn
- $952.97m
- $509.34m
- 42
- 24
- 21
- 19
Annual income statement for Novocure, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 351 | 494 | 535 | 538 | 509 |
| Cost of Revenue | |||||
| Gross Profit | 263 | 388 | 420 | 423 | 381 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 352 | 464 | 579 | 627 | 742 |
| Operating Profit | -0.914 | 30.4 | -44.3 | -89.5 | -233 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.82 | 18.1 | -52.1 | -81.8 | -192 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.23 | 8.54 | -58.4 | -92.5 | -207 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -7.23 | 19.8 | -58.4 | -92.5 | -207 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.23 | 19.8 | -58.4 | -92.5 | -207 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.074 | 0.078 | -0.564 | -0.882 | -1.95 |